Eritoran Tetrasodium

N/A

Report date: 2023/09/01 20:00:50
NME

Base Information

Drug NameEritoran Tetrasodium
Drug Alias Name依立托仑Eritoraneritoranum依立托兰B-1287 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 4 antagonists
TargetsToll like receptor 4
Therapy Area/IndicationsSystemic Inflammatory Response SyndromeInsulin ResistanceLeukemia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUT Health San Antonio
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUT Health San AntonioEisai Inc
Active IndicationsN/A
Inactive IndicationsSystemic Inflammatory Response SyndromeInsulin ResistanceLeukemia +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG